Back to Search Start Over

Prospective virtual screening combined with bio-molecular simulation enabled identification of new inhibitors for the KRAS drug target.

Authors :
Ajmal A
Alkhatabi HA
Alreemi RM
Alamri MA
Khalid A
Abdalla AN
Alotaibi BS
Wadood A
Source :
BMC chemistry [BMC Chem] 2024 Mar 25; Vol. 18 (1), pp. 57. Date of Electronic Publication: 2024 Mar 25.
Publication Year :
2024

Abstract

Lung cancer is a disease with a high mortality rate and it is the number one cause of cancer death globally. Approximately 12-14% of non-small cell lung cancers are caused by mutations in KRAS <superscript>G12C</superscript> . The KRAS <superscript>G12C</superscript> is one of the most prevalent mutants in lung cancer patients. KRAS was first considered undruggable. The sotorasib and adagrasib are the recently approved drugs that selectively target KRAS <superscript>G12C</superscript> , and offer new treatment approaches to enhance patient outcomes however drug resistance frequently arises. Drug development is a challenging, expensive, and time-consuming process. Recently, machine-learning-based virtual screening are used for the development of new drugs. In this study, we performed machine-learning-based virtual screening followed by molecular docking, all atoms molecular dynamics simulation, and binding energy calculations for the identifications of new inhibitors against the KRAS <superscript>G12C</superscript> mutant. In this study, four machine learning models including, random forest, k-nearest neighbors, Gaussian naïve Bayes, and support vector machine were used. By using an external dataset and 5-fold cross-validation, the developed models were validated. Among all the models the performance of the random forest (RF) model was best on the train/test dataset and external dataset. The random forest model was further used for the virtual screening of the ZINC15 database, in-house database, Pakistani phytochemicals, and South African Natural Products database. A total of 100 ns MD simulation was performed for the four best docking score complexes as well as the standard compound in complex with KRAS <superscript>G12C</superscript> . Furthermore, the top four hits revealed greater stability and greater binding affinities for KRAS <superscript>G12C</superscript> compared to the standard drug. These new hits have the potential to inhibit KRAS <superscript>G12C</superscript> and may help to prevent KRAS-associated lung cancer. All the datasets used in this study can be freely available at ( https://github.com/Amar-Ajmal/Datasets-for-KRAS ).<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
2661-801X
Volume :
18
Issue :
1
Database :
MEDLINE
Journal :
BMC chemistry
Publication Type :
Academic Journal
Accession number :
38528576
Full Text :
https://doi.org/10.1186/s13065-024-01152-z